Santen Pharmaceutical Co (SNPHY)
Santen Pharmaceutical Co., Ltd. is a Japanese healthcare company focused on pharmaceuticals and medical devices, with operations across Japan, China, wider Asia, Europe, the Middle East, Africa, and other international markets. The company’s research and development, manufacturing, and marketing activities are centered on eye care, including treatments for glaucoma, ocular hypertension, allergic conjunctivitis, vernal keratoconjunctivitis, and related conditions. Its portfolio includes marketed products such as tafluprost/timolol maleate and ciclosporin, along with additional ophthalmic candidates in various stages of development, including late-stage programs for glaucoma and ocular hypertension, ptosis, juvenile myopia, dry eye, and other eye disorders. The listed security is an OTC Markets depositary receipt representing common stock of Santen Pharmaceutical Co.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-SNPH.Y
|
$12.73
|
5.7% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
17.6x
|
2.2x
|
2.3x
|
4 B
|
3.631 B
|
5.0%
|
93.7%
|
11.3
|
33.8%
|
98.1%
|
